



Sanofi has been a leader in vaccines for over 100 years.

The combination of our innovative vaccines and global reach means that many diseases do not hold the power they once did. Our determination to improve public health motivates us to develop new vaccines to address still unmet medical needs. Fueled by new data and digital technologies, our science and manufacturing have the potential to transform the practice of medicine for millions of people around the world.


Sanofi *Vaccines Profile* 2023



Over half a billion people vaccinated annually with our vaccines worldwide




World-class partnerships with major universities, research institutes, government bodies, international health organizations and patient associations



A world leader in influenza and pediatrics vaccines



Aiming to save *330 tons* of plastic per year and achieve *carbon neutrality by 2030*



10 new vaccines in clinical trials by 2025, including *6 using mRNA technologies*



€7.2 billion in sales in 2022




395 million supply of polio vaccines to UNICEF since 2014



Our vaccines are available in about *150 countries*

Our *Presence*



Industrial Sites

- More than **2.5 million** doses of vaccines produced daily
- **12** sites
- More than **60%** of our employees work in manufacturing and quality

R&D Sites

- **> 500 million** euros invested every year
- **5** main sites
- **9%** of our employees

About Sanofi

Our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. And to never settle. Fueled by data and digital technologies, our cutting-edge science and manufacturing have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world. By chasing the miracles of science to improve people's lives, we surprise ourselves with what we can achieve. And when we discover the extraordinary, we're already planning where to go next.



EVolutive Facilities:

Fully digitalized, our EVolutive Facilities (EVF) will enable more responsive and flexible manufacturing across multiple vaccine and biological platforms including mRNA, while minimizing our impact on the environment. Our EVFs will help improve people's lives by giving them faster access to more vaccines and treatments.